The latest price target for Camp4 Therapeutics (NASDAQ:CAMP) was reported by Rodman & Renshaw on April 14, 2026. The analyst firm set a price target for $7.00 expecting CAMP to rise to within 12 months (a possible 49.25% upside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for Camp4 Therapeutics (NASDAQ:CAMP) was provided by Rodman & Renshaw, and Camp4 Therapeutics initiated their buy rating.

There is no last upgrade for Camp4 Therapeutics

The last downgrade for Camp4 Therapeutics Corp happened on September 16, 2025 when JP Morgan changed their price target from N/A to N/A for Camp4 Therapeutics Corp.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Camp4 Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Camp4 Therapeutics was filed on April 14, 2026 so you should expect the next rating to be made available sometime around April 14, 2027.

While ratings are subjective and will change, the latest Camp4 Therapeutics (CAMP) rating was a initiated with a price target of $0.00 to $7.00. The current price Camp4 Therapeutics (CAMP) is trading at is $4.69, which is within the analyst’s predicted range.